Search Videos and More
Video
Trial 20-153: SACI-IO for Hormone Receptor Positive Metastatic Breast Cancer
Why test the combination of Trodelvy and pembrolizumab?
News
Study Underscores Need for Multidisciplinary Care for COVID-19 Long-Haulers
Physicians across the country have analyzed the emerging scientific data about the long-term effects of COVID-19, creating an initial knowledge base about the clinical experiences of so-called “long-haulers” – patients with COVID-19 who experience prolonged symptoms and/or the emergence of new ones well after the initial viral infection has resolved. A comprehensive review published today in Nature Medicine offers an initial glimpse of the multi-organ effects of long-term COVID-19 and suggests a framework for the care of COVID-19 long-haulers through dedicated, multidisciplinary clinics.
Video
New Treatments for Bladder Cancer Patients
Bladder cancer therapies, once very limited, now offer more options to treat patients than ever before. Dana-Farber Cancer Institute's Bladder Cancer Director, Guru Sonpavde, MD, details new treatments and research initiatives on the horizon for bladder cancer.
News
Dana-Farber Research Leads to Better Understanding of the Immune System in Kidney Cancer
In the last two decades, immunotherapy has emerged as a leading treatment for advanced renal carcinoma cancer (more commonly known as kidney cancer). This therapy is now part of the standard of care, but it doesn’t work for all patients, and almost all patients, no matter how they respond initially, become more resistant to treatment over time.
News
New Targeted Agent Achieves Impressive Response Rate in Trial with Patients with Uterine Serous Carcinoma
In its first clinical trial in patients with a hard-to-treat form of uterine cancer, a targeted drug that subjects tumor cells to staggering levels of DNA damage caused tumors to shrink in nearly one-third of patients, investigators at Dana-Farber Cancer Institute reported.
Video
Next Questions: Chronic Lymphocytic Leukemia
Jennifer Brown, MD, PhD, shares about multiple treatments and drug therapies and how long patients can remain on them while determining the best outcomes.
News
Dana-Farber to Offer First CAR T-Cell Therapy for Indolent Follicular Lymphoma Following FDA Approval
The Food and Drug Administration (FDA) approval of the first CAR T-cell therapy for indolent follicular lymphoma, a slow growing, non-Hodgkin lymphoma (NHL), represents a key advance for patients with relapsed or refractory forms of the disease. Dana-Farber/Brigham and Women’s Cancer Center (DF/BWCC) will be a certified treatment center for the therapy.
News
Immunotherapy Combination Improves Outcomes in Advanced Kidney Cancer
An immunotherapy agent combined with a tyrosine kinase inhibitor drug significantly improved progression-free survival and reduced the risk of death compared to a single agent treatment in advanced kidney cancer patients.
News
Break Through Cancer Launches Collaborative Model Across Top U.S. Research Institutions in Pursuit of Cancer Cures
Break Through Cancer today announced its formal launch as a public foundation designed to find new solutions to the most intractable challenges in cancer.
News
CAR T-Cell Therapy Generates Lasting Remissions in Patients with Multiple Myeloma
In a major advance in the treatment of multiple myeloma, a CAR T-cell therapy has generated deep, sustained remissions in patients who had relapsed from several previous therapies, an international clinical trial has found.
Video
Post-Radical Prostatectomy (RP) Outcome for Patients with High-Risk Prostate Cancer Treated with Intense Neoadjuvant Hormone Therapy (NHT): Results of a Pooled Analysis of Contemporary Clinical Trials
Prostate cancer research: Mary-Ellen Taplin, MD details prostate cancer research findings that indicate decreased PSA relapse rate for patients with a favorable pathologic response to neoadjuvant hormone therapy prior to radical prostatectomy.
Video
An Open-Label, Multicenter, Phase IIIb Study of Patients with Urinary Tract Carcinoma (UTC) (STRONG): Final Analysis for Fixed-Dose Durvalumab Monotherapy (Module A)
Bladder Cancer: Guru Sonpavde, MD details STRONG study results presented at ASCO #GU21? that find fixed-dose durvalumab monotherapy safe in patients previously treated for urinary tract carcinoma. Abstract 429